RCS - Angle PLC - EACR 2025: Data demonstrating DNA dual analysis

AngleAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250617:nRSQ0767Na&default-theme=true

RNS Number : 0767N  Angle PLC  17 June 2025

 For immediate release  17 June 2025

 

ANGLE plc ("the Company")

 

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR
COMPREHENSIVE LIQUID BIOPSY PROFILING

 

Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour
heterogeneity in lung cancer patients

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) solutions for use in research, drug
development and clinical oncology, is pleased to announce the presentation of
a poster at the European Association for Cancer Research (EACR) Congress,
taking place in Lisbon, Portugal from 16-19 June 2025.

 

The poster entitled 'Comparative molecular analysis of CTCs and cfDNA
Detection using Parsortix(®) system' is being presented during the Biomarkers
in Tissue and Blood session on Tuesday 17 June 2025.

 

This poster builds on work first presented in a February 2025 webinar hosted
by Illumina as part of a co-marketing initiative. It showcases an end-to-end
Illumina-based DNA dual analysis workflow for the analysis of CTCs harvested
using ANGLE's Parsortix system, alongside circulating tumour DNA (ctDNA),
using a 79-gene lung cancer panel on the Illumina NextSeq2000 platform.
Illumina is the world's largest provider of NGS systems and assays, with an
installed base of over 25,000 sequencing systems across more than 9,500
customers in 155 countries. The study provides a practical example of how
Illumina customers could integrate DNA dual analysis of CTCs and ctDNA into
existing sequencing pipelines for deeper insights into tumour heterogeneity.

 

The first phase of the study established analytical sensitivity and
specificity using contrived samples, where cancer cells were added at defined
levels (0, 2, 5, 10, and 20 cells) to blood from healthy volunteers. The
samples were processed with the Parsortix system, and DNA from isolated cells
was analysed for seven clinically relevant mutations. Druggable mutations such
as BRAF, EGFR, and TP53 were consistently detected confirming high sensitivity
of the workflow.

 

The second phase of the study analysed blood from 27 lung cancer patients. DNA
was extracted from both CTCs and plasma in each sample, then sequenced using a
79-gene lung cancer panel. The results showed substantial differences between
the two analytes with 53% of mutations found in CTCs alone, 36% in ctDNA alone
and 11% found in both analytes. These findings evidence that CTC-DNA and ctDNA
provide distinct and complementary information, with many druggable targets
found in CTC-DNA including CHEK2 (olaparib from AstraZeneca and Merck and
talazoparib from Pfizer), ESR1 (elacestrant from Menarini), NTRK1
(larotrectinib from Bayer and entrectinib from Roche) and RET (selpercatinib
from Eli Lilly and pralsetinib from Blueprint Medicines).

 

This study demonstrates ANGLE's unique ability to deliver DNA dual analysis
from a single blood sample, revealing clinically relevant mutations missed by
ctDNA alone. By enabling a more complete view of tumour genetics, molecular
analysis of CTC-DNA and ctDNA using the Parsortix system offers biopharma
partners a valuable tool for identifying resistance, stratifying patients, and
improving trial outcomes.

 

The poster will be available on ANGLE's website from 20:00 on Tuesday 17 June:
https://angleplc.com/resources/posters/
(https://angleplc.com/resources/posters/)

 

ANGLE Chief Scientific Officer, Karen Miller, commented:

"This study demonstrates the unique value of ANGLE's DNA dual analysis
approach, which combines sequencing of CTC-DNA and ctDNA from the same blood
sample to uncover critical differences in tumour biology. Building on our
collaboration with Illumina, this workflow enables broad NGS-based molecular
profiling and delivers insights that can help pharma customers identify drug
targets, treatment resistance, stratify patients and minimise invasive tissue
biopsy requirements for study participants."

 

 

For further information:

 

 ANGLE plc                               +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Broker)            +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Ciara Martin              +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                +1 (212) 850 5624

 

 

For Research Use Only. Not for use in diagnostic procedures.

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

 

Any reference to regulatory authorisations such as FDA clearance, CE marking
or UK MHRA registration shall be read in conjunction with the full intended
use of the product:

 

The Parsortix(®) PC1 system is an in vitro diagnostic device intended to
enrich circulating tumor cells (CTCs) from peripheral blood collected in
K(2)EDTA tubes from patients diagnosed with metastatic breast cancer.  The
system employs a microfluidic chamber (a Parsortix cell separation cassette)
to capture cells of a certain size and deformability from the population of
cells present in blood.  The cells retained in the cassette are harvested by
the Parsortix PC1 system for use in subsequent downstream assays.  The end
user is responsible for the validation of any downstream assay.  The
standalone device, as indicated, does not identify, enumerate or characterize
CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs,
including monitoring indications or as an aid in any disease management and/or
treatment decisions.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABCGDLSDBDGUL